The clinical feasibility of this approach was demonstrated in the GINAKIT2 trial conducted by Heczey and colleagues, where autologous GD2 CAR-iNKT expressing IL-15 were manufactured for children with neuroblastoma. The gene discussed is IL15; the disease is neuroblastoma.